Johnson & Johnson reports Q4 2024 and Full-Year 2024 results
2025年1月22日 · New Brunswick, N.J. (January 22, 2025) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2024. “2024 was a transformative year …
DePuy Orthopaedics | DePuy Synthes - Johnson & Johnson …
DePuy Synthes, the Orthopaedics Company of Johnson & Johnson, provides one of the most comprehensive Orthopaedics portfolios in the world that helps heal and restore movement for …
Johnson & Johnson Reports Q4 and Full-Year 2024 Results
2025年1月22日 · NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2024. "2024 was a …
TRUESPAN™ Meniscal Repair System | DePuy Synthes
Available in 0°, 12° and 24° needles pre-loaded with PEEK implants and 2-0 partially absorbable ORTHOCORD™ Suture. Small-size needle and implants minimize tissue disruption and …
DePuy Synthes | J&J MedTech - Johnson & Johnson Medical …
Designed for ease of use in ACL reconstruction, the RIGIDLOOP™ BTB Adjustable Cortical System brings the benefits of adjustable suspensory fixation to BTB procedures, quadriceps …
What you need to know about - Johnson & Johnson
2025年1月22日 · This morning, Johnson & Johnson shared its 2024 fourth-quarter and full-year earnings report. Since its founding in 1886, the company has been committed to …
Johnson & Johnson reports Q3 2024 results
2024年10月15日 · Johnson & Johnson is updating its 2024 guidance, including adjusted operational EPS guidance, to reflect improved performance and the impact from the recent …
首个！疗效持久达一年，强生10亿美元引进口服多肽积极试验结果 …
2024年3月12日 · 2023年公布的FRONTIER 1研究的结果显示，在第16周，接受JNJ-2113治疗的患者中，达到银屑病面积与严重程度指数（PASI）改善至少75%的受试者的比例（PASI 75，主 …
JNJ-77242113, a highly potent, selective peptide targeting the IL …
JNJ-77242113 is a peptide targeting the IL-23 receptor with high affinity (K D: 7.1 pM). In human cells, JNJ-77242113 potently and selectively inhibited proximal IL-23 signaling (IC 50:...
Johnson & Johnson reports Q2 2024 results | Johnson & Johnson …
2024年7月17日 · Johnson & Johnson is updating its 2024 guidance, including adjusted operational EPS guidance, to reflect improved performance and the impact for the recent …
- 某些结果已被删除